Zhifei Longcom Recombinant COVID-19 Vaccine Receives Marketing Approval in Kenya

Release time:2022-12-23  |  Click rate:

On December 22, the Company's Recombinant COVID-19 Vaccine (CHO Cell) was approved for marketing by the Pharmacy and Poisons Board (PPB) of Kenya, becoming the first recombinant protein COVID-19 vaccine marketed in Kenya.

So far, more than 300 million doses of Zhifei Longcom Recombinant COVID-19 Vaccine (CHO Cell) have been used globally, with Emergency Use Authorization (EUA) granted in Indonesia and Colombia, booster dose authorization in Indonesia, and Marketing Approval in Uzbekistan and Kenya.

The results of the Phase III clinical trial of Zhifei Longcom Recombinant COVID-19 Vaccine (CHO Cell) show that the vaccine efficacy against COVID-19 of any severity reach 81.4%, with 100% protection against death; In people aged 18 to 59, the vaccine efficacy is 81.2%; In people aged 60 and above, the vaccine efficacy is 87.6%1.

A study published in The New England Journal of Medicine, one of the world's top academic journals, shows that Zhifei Longcom Recombinant COVID Vaccine (CHO Cell) can still produce a very good neutralization effect on Omicron variants with severe immune escape2.

On December 14, the comprehensive working group under the State Council's Joint Prevention and Control Mechanism issued the Implementation Plan of the Second Booster Dose of COVID-19 Vaccination. The Recombinant COVID-19 Vaccine (CHO Cell) of Zhifei Longcom is prioritized selected by the nation as the second booster dose of COVID-19 vaccine for those who received three doses of the inactivated vaccine.

In the future, Zhifei will continue to adhere to the corporate principle of "prioritizing social benefits over corporate profits", and continue to promote the internationalization strategy. In this way, the vaccines by Zhifei with greater amount, safer profile and better quality can benefit people worldwide, and contribute more to global public health and epidemic prevention and control.